TKA adjunct analgesia: selected evidence and interpretation
Educational work by a pre-medical student — not medical advice. Not a clinical protocol, prescription, or patient handout, and not for patient care. See DISCLAIMER.
Independent educational portfolio. Revised 27 October 2026. This note replaces the earlier dose-based opioid-free pathway discussion after source inconsistencies were identified. It is a selected-source analysis, not a clinical pathway, systematic review, or validated device input.
Define the comparison
Avoiding opioids during surgery differs from eliminating all perioperative opioids. Postoperative rescue, background spinal/regional analgesia and other medicines must be described before comparing outcomes. A reduction in opioid use does not alone establish better pain control, function, safety or prevention of long-term opioid use.
Procedure-specific guidance
PROSPECT 2022, PMID 35852550 supports a multimodal TKA framework and evaluates each intervention within that context. It does not recommend routine gabapentinoids, and it does not recommend ketamine, citing conflicting procedure-specific evidence. Its procedure-specific conclusions should not be replaced by generic mixed-surgery efficacy claims. This summary does not reproduce the guideline or its exceptions.
An informative randomized trial
Muñoz-Leyva et al., "No Benefits of Adding Dexmedetomidine, Ketamine, Dexamethasone, and Nerve Blocks to an Established Multimodal Analgesic Regimen after Total Knee Arthroplasty," Anesthesiology 2022;137(4):459-470, PMID 35867857 randomized 78 TKA patients to an established regimen with or without five additional interventions, including ketamine, dexmedetomidine and additional regional/anti-inflammatory components. It did not demonstrate further benefit in opioid consumption, pain or recovery and reported more hypotension in the add-on group.
Because several interventions changed together, the trial cannot determine each component's independent effect. A nonsignificant difference is not equivalence, non-inferiority or proof of zero benefit. The results apply to the studied population and background regimen.
Lidocaine and regional anesthesia
Foo et al., international consensus addresses perioperative IV lidocaine safety. It should not be treated as a universally safe adjunct to local-anesthetic blocks. This portfolio supplies no infusion rates, timing intervals or combined-local-anesthetic regimen.
Withdrawn assertions
The earlier document cited PMID 23364596 as a Farag TKA lidocaine trial. That identifier does not correspond to a TKA lidocaine trial, so the claimed trial results are removed. The previous unsupported numerical efficacy estimates, fixed patient-selection criteria, processed-EEG safety guarantee, GRADE A–D labels and medication dosing are also withdrawn rather than retained behind a disclaimer.
No robot-assisted TKA efficacy, absence of all relevant trials, FDA regulatory classification or patient-level treatment recommendation is asserted. Other documents in the series retain their own source-audit requirements.